VEGF as a mediator of tumor-associated immunodeficiency.
about
Gene Therapy Applications to Cancer TreatmentExpression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USAModulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cellsInhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical DataAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentCancer immunotherapy: how low-level ionizing radiation can play a key role.Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer modelAACR centennial series: the biology of cancer metastasis: historical perspectiveExpression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.Single vs. combination immunotherapeutic strategies for glioma.Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation.Targeting inhibitory pathways in cancer immunotherapy.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceAntiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma modelCombination immunotherapy: a road map.Dendritic cell subsets in health and disease.GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.Bevacizumab plus ipilimumab in patients with metastatic melanoma.The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.Using antibodies in tumour immunotherapy.Monoclonal antibody therapy of ovarian cancer.Immunotherapy for pancreatic cancer - science driving clinical progress.Immunotherapy of malignant brain tumors.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.The immunosuppressive side of PDTConcomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.Dendritic cells and tumor microenvironment: a dangerous liaisonSingle agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastomaImmune resistance orchestrated by the tumor microenvironment.Targeting the tumour microenvironment in ovarian cancerVascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.
P2860
Q24792808-60EAD19C-4674-4202-AF2D-1A7A4D3C7FE5Q24793622-6E4B2952-3A29-4276-97C5-8834CA7D5630Q24813407-ADBEAFDE-CBDD-49AA-BD53-0D329E191692Q26781098-E0BD96D2-0CDB-4AC9-AF4F-7BB5078FECBCQ27024830-1AEAF381-54E7-4989-8618-1AFE7EFABC15Q27335110-2B3752F3-21BA-4B20-BFD1-FEC001732041Q28066199-D0A37E8E-3D2E-4159-97B9-A1E7BCCDD22AQ28241308-429A7805-58E6-4F05-88B1-011F484BEFE8Q30235014-9B8CD592-0616-4D54-B188-DFC29D900964Q33517133-B5C5489E-FFD7-41D5-998A-C737686FFB69Q33683443-C7DDFB31-A89C-4FFE-9B85-6ED7476C7535Q33690926-0C59C261-AE23-4B09-BA6A-577A8725687BQ33746041-35F8E35F-027C-4E14-836F-5F43E9F78B4CQ33757576-021BD568-C760-4A47-98CB-F94412EC56CDQ33950640-94439F8A-933A-4E2C-B8FB-A213CD9F9D2CQ33996674-0222F14D-47A4-4EB8-B0BE-67BEE42B71E0Q34031748-7C7A7C6E-31E4-45F1-9E7F-475741FD3173Q34093354-DC8259FE-BF53-44D5-A6C0-8B2F817E3D16Q34552128-06C110FA-CDBB-40A7-ABD8-53165117EC6EQ34582889-8099493E-6A4A-47EE-9885-24C9036857DDQ34591128-758080F6-15C4-4E35-8863-BD413F389918Q35012765-99470D20-DB7F-4656-9D53-C8A940BBDF04Q35652459-0F14D10D-A139-4482-8AC9-7D8D57A4D6E7Q35831115-1121D25F-C7D0-4B19-A1CE-D4D1F8BB3DC3Q35842612-6ADA005E-6DBC-4D7B-91EB-CAA08BFE603FQ36066157-BCB3D6AF-873B-4DDB-8A30-78EC4354AB2BQ36133140-33CFEE7E-9DE9-4490-8ED3-F82768B727C9Q36162929-4FD1BACE-A3AA-49B8-B691-CC5CB20EF95AQ36224057-C6C82B9A-2C51-4739-A7A5-8F45BC597B14Q36231512-45C768D7-DDF7-4348-9A6A-07D1DF14F494Q36567697-89EC752B-AEC4-46C5-A1E1-B068C2F5E372Q36569018-A4077DF7-3FAF-4747-A7EA-1F2CA6566BAAQ36575238-9076E8CD-4B2F-445D-8D17-095D61D83361Q36593747-73C3D83F-F8E4-4597-871F-B35444F72383Q36626921-C13678D9-AAC0-4EAA-930A-9764A3D0B2B8Q36764907-670EB797-10E9-4EAD-8C34-2A94E1DF64A1Q36958112-422A4F6A-A3AF-43F7-BECC-8D69014B5196Q37012084-59C0F6B2-AB60-456E-A75A-F3EE3BE6A13FQ37024656-6725AA29-2882-4EEF-B489-25E4DC7A6BA4Q37051022-CCD90FF3-C112-4AB7-9334-D166D348E00D
P2860
VEGF as a mediator of tumor-associated immunodeficiency.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
VEGF as a mediator of tumor-associated immunodeficiency.
@ast
VEGF as a mediator of tumor-associated immunodeficiency.
@en
VEGF as a mediator of tumor-associated immunodeficiency.
@nl
type
label
VEGF as a mediator of tumor-associated immunodeficiency.
@ast
VEGF as a mediator of tumor-associated immunodeficiency.
@en
VEGF as a mediator of tumor-associated immunodeficiency.
@nl
prefLabel
VEGF as a mediator of tumor-associated immunodeficiency.
@ast
VEGF as a mediator of tumor-associated immunodeficiency.
@en
VEGF as a mediator of tumor-associated immunodeficiency.
@nl
P356
P1433
P1476
VEGF as a mediator of tumor-associated immunodeficiency.
@en
P2093
P2888
P304
P356
10.1385/IR:23:2-3:263
P577
2001-01-01T00:00:00Z
P6179
1051618180